Company’s Latest Proprietary NanoMetalene-Coated Device Combines Benefits of Titanium and PEEK in One Spinal TLIF Implant
CARLSBAD, Calif. / June 15, 2016 – SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of its Hollywood™ VI NanoMetalene® transforaminal lumbar interbody fusion device.
Hollywood VI NanoMetalene, which is commercially available and has been successfully implanted, is indicated for use in spinal fusion procedures at one or two contiguous levels (L2-S1) in skeletally mature patients with degenerative disc disease (DDD). It is the most recent device to leverage SeaSpine’s exclusive rights to the NanoMetalene technology within the spine market. This implant adds to the NanoMetalene family of products, which already includes the Hollywood NanoMetalene, Ventura™ NanoMetalene and cervical Cambria™ NanoMetalene interbody devices.
NanoMetalene is a sub-micron layer of commercially pure titanium molecularly bonded to a PEEK-OPTIMA® polymer from INVIBIO®. It is applied in a proprietary high-energy, low-temperature surface process, which is different than other coating applications and allows for titanium nano topography to encompass the entire implant. The NanoMetalene coating provides the surface benefits of titanium while retaining the benefits associated with traditional PEEK-OPTIMA devices such as biocompatibility, modulus of elasticity similar to bone, and excellent radiographic visibility for post-op imaging.
“Surgeon response to our NanoMetalene family of implants has been overwhelmingly positive – in part because this technology offers the best features of titanium and PEEK in an interbody solution that we believe supports bone growth,” said Keith Valentine, CEO of SeaSpine. “We will continue to expand our NanoMetalene offering throughout 2016 and into 2017 to ensure this differentiated technology is available for all interbody spine procedures.”
With a curved, anatomically geometric shape, the Hollywood VI NanoMetalene implant is well-suited for placement in the anterior column of the spine. This variable insertion (VI) design facilitates final implant placement within the disc space and provides TLIF surgeons options tailored for their patients. Hollywood VI NanoMetalene also features a completely coated graft aperture for autogenous bone graft for fusion.
SeaSpine expects to launch additional NanoMetalene coated PEEK interbody devices in future periods.
NanoMetalene and SeaSpine are registered trademarks of SeaSpine Orthopedics Corporation or its subsidiaries in the United States and/or other countries. Hollywood, Ventura, Cambria, and the SeaSpine logo are trademarks of SeaSpine Orthopedics Corporation or its subsidiaries. PEEK-OPTIMA is a registered trademark of Invibio and is used by SeaSpine under license.
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal hardware portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal fusion hardware product development helps SeaSpine to offer its surgeon customers a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.
SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to: expected benefits of the NanoMetalene products, including with respect to bone growth; future expansion of NanoMetalene product offerings throughout 2016 and 2017; the ability to ensure NanoMetalene technology is available for all interbody spine procedures; and expectations regarding the launch of additional NanoMetalene-coated PEEK interbody devices in future periods. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to, surgeons’ willingness to continue to use existing NanoMetalene products and to adopt future NanoMetalene products; delays in launching new NanoMetalene products, including as a result of difficulties in obtaining regulatory clearance of products in development; the potential that NanoMetalene products may not demonstrate adequate safety or efficacy, independently or relative to competitive products; the risk of supply shortages, including as a result of our dependence on an independent third-party to perform the proprietary NanoMetalene process for our benefit; our ability to obtain funding on a timely basis on acceptable terms, or at all, to execute our business strategy; general economic and business conditions in the markets in which we do business, both in the U.S. and abroad; and other risks and uncertainties more fully described in our news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.
# # #
Kate Hillman / SeaSpine
firstname.lastname@example.org / 949-422-5033
Kirsten Lesak-Greenberg / PadillaCRT
email@example.com / 212-421-8320